Home Featured

Featured

Random

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022

‘Pharmacopeia’ Season Finale Features Cutting Edge Psychedelic Research

Buried Treasure: How Does Psilocybin Reduce Compulsivity?

PT279 – Joe Zap & Kevin Whalen – Cannabis Acceptance, Conspiratorial Thinking, and Psychedelic Podcasting

Breakthrough Data, Black Box Sessions: A Closer Look at MindMed’s Phase 2b LSD for GAD Study

Mindset Pharma Files a Sixth U.S. Provisional Patent, Further Expanding Its...

MINDCURE’s Proprietary Bioinformatics Platform, PsyCollage, Beta Tested and Deployed for Product...

PT458 – When Science, Society, and Policy Collide

Reunion Neuroscience Inc. Obtains Final Court Order for Proposed Plan of Arrangement

Massachusetts General Hospital to Study How Psychedelics Influence the Brain

Israeli Based Biotech Company Clearmind Medicine Inc’s CEO, Dr. Adi Zuloff-Shani,...

Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking...

PTSF63 – The Media and Legalization, Joints for Jabs, and 40,000...

Psyched Wellness Commences Neurobehavioral Preclinical Trial Study on AME-1

MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use...

12 3...300 Page 1 of 300

Pα+ Psychedelic Bulletin #212: Delix Posts Early Efficacy Signal; NRx Wants...

Q3’25 Psychedelic Lobbying Update

Jennifer Espenscheid — Art as a Practice, Psychedelics as a Teacher

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.